Amphista Therapeutics and Bristol Myers Squibb partner for development of protein degradation therapeutics
pharmafile | May 4, 2022 | News story | Research and Development |
Amphista and Bristol-Myers Squibb have announced a strategic collaboration and license agreement.
Under the terms of the collaboration, BMS and Amphista will work collaboratively to discover and develop small molecule protein degraders. BMS will be granted a global exclusive license to the degraders developed, and will be responsible for the further development and commercialisation activities.
Amphista will receive a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments, and payment for a limited expansion of the collaboration, alongside royalties on global net sales of products.
TPD therapies are designed to use physiological mechanisms to remove pathogenic protein from the body, offering the potential to access many disease targets previously considered “undruggable”.
Nicola Thompson, CEO of Amphista, commented, “Our collaboration with Bristol Myers Squibb is a powerful validation of our advances in TPD research and the capabilities of our Eclipsys next-generation TPD platform. Combining our expertise with Bristol Myers Squibb’s strong legacy and experience in the protein degradation space brings new promise to the potential of delivering more effective new treatments to patients seeking treatment options.”
“Bristol Myers Squibb continues to build its leadership and scientific expertise in the protein degradation space,” added Rupert Vessey, MA, BM, BCh, FRCP, D Phil, Executive Vice President, Research & Early Development, Bristol Myers Squibb. “We look forward to collaborating with Amphista and using its TPD platform to potentially develop new targeted protein degradation therapies.”